Ropinirole Controlled Release (CR) as an Adjunctive Agent in the Treatment of Major Depression

• Status: Completed
• Trial end date: 2007-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This is an 8 week study for patients who are currently taking antidepressant medication but not fully responding. Ropinirole CR would be taken in conjunction with current antidepressant medication. Patients come into the clinic once a week when starting on the medication and then once every other week for the remainder of the 8 weeks.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Stanford University
• Collaborators: Duke University; GlaxoSmithKline
• Treatments: Ropinirole

Criteria

Inclusion Criteria:

• Age 18 to 65 years old

• Currently experiencing major depression

• On at least an adequate dose of fluoxetine, paroxetine, sertraline, citalopram, escitalopram, venlafaxine, bupropion, mirtazapine or duloxetine for at least 6 weeks (monotherapy). Exclusion Criteria:1. Pregnant females or females of child bearing years not using adequate birth control in the opinion of the investigators

• Known sensitivity to ropinirole

• Significant medical conditions that would preclude safe participation in the study in the opinion of the investigators.

• Significant abnormalities observed in screening laboratory evaluation